Dihydroartemisinin can lead to the inhibition of NSCLC metastasis via glucose metabolism modulation, specifically by inhibiting the NF-κB pathway, causing dihydroartemisinin to be a promising NSCLC treatment [120]. Here, NFKB1 is linked to non-small cell lung carcinoma.